[Cost-effectiveness of human papillomavirus vaccination in South Korea]
Lee YJ, Kim JM, Park JY, Kim YJ, Kim Y
Record ID 32013000523
Korean
Original Title:
인유두종 바이러스(HPV) 백신의 경제성 분석
Authors' objectives:
The purpose of this study is to provide evidence for rational decision making through conducting the economic evaluation of HPV vaccine by societal perspective.
Authors' recommendations:
Based on the assumption that the cost of the vaccine after introduction of the vaccination program would decrease to 70% of its current price, the incremental cost-effectiveness ratio of the vaccination of 13-year-old girls was $32,000 per quality-adjusted life-year (QALY) gained, as compared with the current screening practice. Therefore, the vaccination program is not cost-effective in Korea given the cost-effectiveness threshold of GDP per capita ($23,680). The sensitivity analysis showed that the price, the effectiveness of vaccination and discount rate affected the result.
Details
Project Status:
Completed
Year Published:
2013
URL for published report:
https://www.neca.re.kr/lay1/program/S1T11C145/report/view.do?seq=88
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
South Korea
MeSH Terms
- Humans
- Papillomavirus Vaccines
- Korea
- Papillomavirus Infections
- Cost-Benefit Analysis
Contact
Organisation Name:
National Evidence-based healthcare Collaborating Agency
Contact Address:
National Evidence-based Healthcare Collaborating Agency (NECA), 3~5F Health and Welfare Social Administration B/D, 400 Neungdong-ro, Gwangjin-gu, Seoul, Korea.
Contact Name:
int@neca.re.kr
Contact Email:
int@neca.re.kr
Copyright:
National Evidence-based Healthcare Collaborating Agency (NECA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.